The prototype selective antagonist of CXCR4, AMD3100 (Plerixafor) [26], was reported to inhibit apoptosis of breast cancer cells by CXCR4-tropic HIV [10], and other inhibitors of CXCR4 are currently in development to treat various cancers [27]–[29]. Here, CXCR4 is linked to cancer.